Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: A randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial

Diabetes, Obesity and Metabolism

Volumn 18, Issue 1, 2016, Pages 100-103

  Marquard, J ^a,b   Stirban, A ^c   Schliess, F ^c   Sievers, F ^c   Welters, A ^a,b,d,e   Otter, S ^a,d,e   Fischer, A ^c   Wnendt, S ^f   Meissner, T ^b   Heise, T ^c   Lammert, E ^a,d,e  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Profil   (Germany)

^d LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^e German Center of Diabetes Research DZD e V   (Germany)

^f MLM Medical Labs GmbH   (Germany)

Author keywords

Antidiabetic drug; DPP IV inhibitor; Insulin secretion; NMDA; Type 2 diabetes

Indexed keywords

DEXTROMETHORPHAN; GLUCAGON; GLUCOSE; INSULIN; PLACEBO; SITAGLIPTIN; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL;

ADD ON THERAPY; ADULT; AREA UNDER THE CURVE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; LETTER; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; AGED; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIA; MIDDLE AGED;

AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DEXTROMETHORPHAN; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; SITAGLIPTIN PHOSPHATE;

EID: 84955176663     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12576     Document Type: Letter

References (10)

1. Marquard J, Otter S, Welters A et al. Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. Nat Med 2015; 21: 363-372.
2. Wollheim CB, Maechler P. Beta cell glutamate receptor antagonists: novel oral antidiabetic drugs? Nat Med 2015; 21: 310-311.
3. Ahrén B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes 2010; 3: 31-41.
4. Rosenstock J, Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007; 14: 98-107.
5. Cefalu WT, Buse JB, Del Prato S et al. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care 2014; 37: 2647-2659.
6. Kahn SE, Carr DB, Faulenbach MV, Utzschneider KM. An examination of beta-cell function measures and their potential use for estimating beta-cell mass. Diabetes Obes Metab 2008; S4: 63-76.
7. Gheni G, Ogura M, Iwasaki M et al. Glutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion. Cell Rep 2014; 9: 661-673.
8. Maechler P, Wollheim CB. Mitochondrial glutamate as a messenger in glucose-induced insulin exocytosis. Nature 1999; 402: 685-689.
9. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37: 2149-2158.
10. Farilla L, Bulotta A, Hirshberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-5158.